BiotechTube

V503

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papillomavirus Infections

Conditions

Papillomavirus Infections

Trial Timeline

Apr 27, 2019 → Feb 28, 2025

NCT ID
NCT03903562

About V503

V503 is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03903562. Target conditions include Papillomavirus Infections.

What happened to similar drugs?

4 of 20 similar drugs in Papillomavirus Infections were approved

Approved (4) Terminated (0) Active (16)
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅GardasilMerckApproved
✅Gardasil-9MerckApproved
✅Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
🔄9vHPV vaccineMerckPhase 3
🔄V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
🔄V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04635423Phase 3Completed
NCT03903562Phase 3Completed
NCT03158220Phase 3Completed
NCT01254643Phase 3Completed
NCT00943722Phase 3Completed

Competing Products

20 competing products in Papillomavirus Infections

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
19
9vHPV vaccineMerckPhase 3
44
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
43
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
40
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
40
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
26
GardasilMerckApproved
43
GardasilMerckPhase 2
35
9vHPV VaccineMerckPhase 3
44
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
40
V503 + GARDASILMerckPhase 3
40
9vHPV VaccineMerckPhase 3
44
Gardasil vaccineMerckPre-clinical
26
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + PlaceboMerckPhase 3
40
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)MerckPhase 3
40
9vHPV vaccineMerckPhase 3
40
Gardasil™ + PlaceboMerckPhase 3
40
V503 + GardasilMerckPhase 3
44
9vHPV vaccineMerckPhase 3
40